Sugi Predict

Sugi Predict / Compounds / SCHEMBL23751

SCHEMBL23751

SCHEMBL23751

CCOC(=O)NC(=S)Nc1nccnc1Cl

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.43
▸ RAB9A P51151 5/20 0.39
▸ NPC1 O15118 3/20 0.39
▸ MAPKAPK2 P49137 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ GAA P10253 1/20 0.37
▸ LMNA P02545 2/20 0.37
▸ HTT P42858 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2021043 0.86 TDP1 (0.38) MAPTRAB9ANPC1MAPKAPK2SMN1; SMN2
SCHEMBL22151008 0.83 RAB9A (0.53) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL26961993 0.81 MAPT (0.44) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL30675731 0.81 MAPT (0.44) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL26131195 0.81 MAPT (0.41) MAPTRAB9ANPC1MAPKAPK2SMN1; SMN2
SCHEMBL31481019 0.81 MAPT (0.49) MAPTRAB9ANPC1MAPKAPK2SMN1; SMN2
SCHEMBL2634411 0.80 RAB9A (0.63) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL11746859 0.78 MAPT (0.44) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL2634882 0.78 RAB9A (0.47) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL11746746 0.78 ALDH1A1 (0.54) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242530-A1 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2023-08-03 — — US disclosed
EP-4198036-A1 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A] PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF F. Hoffmann-La Roche AG (CH) 2023-06-21 — — EP disclosed
EP-3510030-B1 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2023-03-22 — — EP disclosed
WO-2023019430-A1 COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-02-23 — — WO disclosed
EP-3386978-B1 BRIDGED PIPERIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2021-01-27 — — EP disclosed
EP-3386978-B1 BRIDGED PIPERIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2021-01-27 — — EP disclosed
US-20200291034-A1 BRIDGED PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2020-09-17 — — US disclosed
US-20200291034-A1 BRIDGED PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2020-09-17 — — US disclosed
US-20200270248-A1 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2020-08-27 — — US disclosed
CN-107531695-B JAK inhibitors 无锡福祈制药有限公司 2020-03-27 — — CN disclosed
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 — — EP disclosed
US-9079886-B2 Substituted triazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-07-14 — — US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 — — US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 — — US disclosed
EP-2523949-B1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS JANSSEN PHARMACEUTICALS INC (US) 2014-08-20 — — EP disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 — — US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 — — US disclosed
US-20120295891-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-11-22 — — US disclosed
WO-2012025186-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 — — WO disclosed
WO-2011086099-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2011-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200270248-A1 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF JAK1, JAK2, JAK3 MAPT 222/4885RAB9A 2337/4885NPC1 3017/4885
US-20230242530-A1 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF JAK1, JAK2, JAK3 MAPT 222/4885RAB9A 2337/4885NPC1 3017/4885
US-20120295891-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, APH1A MAPT 2296/4885RAB9A 2912/4885NPC1 771/4885
US-20200291034-A1 BRIDGED PIPERIDINE DERIVATIVES PTGDR, HPGDS, PSEN1 MAPT 295/4885RAB9A 1413/4885NPC1 440/4885
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 MAPT 4687/4885RAB9A 3444/4885NPC1 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.